During 2001-2002, research on the pharmacology of marine chemicals continued to be global in nature involving investigators from
Introduction
The purpose of this article is to review the 2001-2002 primary literature on pharmacological and toxicological studies with marine natural products using a similar format to the one used in our previous reviews of the marine pharmacology peer-reviewed literature (Mayer and Lehmann, 2000; Mayer and Hamann, 2002, 2004) . Consistent with our previous reviews, only those articles reporting on the bioactivity and/or pharmacology of 106 marine chemicals whose structures have been published are included in the present review. We have used the same chemical classification as our previous reviews (Schmitz et al., 1993) to assign each marine compound to a major chemical class, namely, polyketides, terpenes, nitrogen-containing compounds or polysaccharides. Those publications reporting on anthelmintic, antibacterial, anticoagulant, antifungal, antimalarial, antiplatelet, antiprotozoal, antituberculosis or antiviral properties of 56 marine chemicals have been tabulated in Table 1 with the corresponding structures shown in Fig. 1 . The articles reporting on 19 marine compounds affecting the cardiovascular, immune and nervous systems, as well as those with anti-inflammatory and antidiabetic effects, are grouped in Table 2 and the structures presented in Fig. 2 . Finally 31 marine compounds targeting a number of distinct cellular and molecular targets and mechanisms are shown in Table 3 and their structures depicted in Fig.  3 . Publications on the biological and/or pharmacological activity of marine extracts or as yet structurally uncharacterized marine compounds have been excluded from the present review, though several promising reports were published during (Duarte et al., 2001 Ermakova et al., 2001; Kaji et al., 2002; Liu et al., 2002b; Matou et al., 2002; Mohapatra et al., 2002; Preeprame et al., 2001; Suput et al., 2001; Trento et al., 2001 ).
Marine compounds with anthelmintic, antibacterial, anticoagulant,
antifungal, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities Table 1 summarizes new pharmacological findings reported during 2001-2002 on the preclinical anthelmintic, antibacterial, anticoagulant, antifungal, antimalarial, anti-platelet, antiprotozoal, antituberculosis, and antiviral pharmacology of the 56 marine natural products shown in Fig. 1. 
Anthelmintic and antibacterial compounds
Two studies contributed to the search of novel anthelmintic marine natural products during [2001] [2002] . Nafuredin (1), an epoxy-δ-lactone with a methylated olefinic side chain isolated from the culture broth of Aspergillus niger, exerted anthelmintic activity against the ruminant parasite worm Haemonchus contortus and the dwarf tapeworm Hymenolepsis nana in mice . The mechanism of action involved inhibition at the nanomolar level of NADH-fumarate reductase activity, a "unique anaerobic electron transport system in helminth mitochondria". The marine natural product onnamide F (2), isolated from the Australian marine sponge Trachycladus laevispirulifer, showed potent inhibition of larval development of the parasitic nematode Haemonchus contortus with an in vitro LD 99 value of Reflecting the fact that the development of resistance toward current antibiotics continues to be a significant problem in the treatment of infectious diseases, during 2001-2002 thirteen studies contributed to the antibacterial pharmacology of marine natural products, a marked increase from 1998-2000 (Mayer and Lehmann, 2000; Mayer and Hamann, 2002, 2004) . Two studies reported on the mechanism of action of two novel marine antibiotics. Torres et al. (2002) investigated the arenosclerins A-C (3-5) and haliclonacyclamine E (6), novel tetracyclic alkylpiperidine alkaloids isolated from the marine sponge Arenosclera brasiliensis. The investigators reported that differences in the stereochemistry at the bispiperidine ring system played a significant role in the potent antibiotic activity of these compounds against antibiotic-resistant Staphylococcus aureus strains, observations that lead the authors to suggest that "these compounds may be regarded as potentially useful new drug leads". Linington et al. (2002) developed a high throughput assay to screen marine compounds for their ability to inhibit a type III secretory system which is an essential component of the pathogenicity of enteropathogenic and enterohermorragic E. coli. Their efforts resulted in the isolation of a novel antimicrobial glycolipid caminoside A (7) from the marine sponge Caminus spaeroconia. Caminoside A was "reasonably potent" against methicillin-resistant S. aureus (MIC=12 μg/mL) and vancomycin-resistant enterococcal strains (MIC=12 μg/mL).
Although additional novel marine antibiotics were reported in [2001] [2002] , no mechanism of action studies were reported for marine compounds (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Nevertheless, the reports highlight the observations that potentially novel antibiotics are present in marine bacteria, tunicates, fungi, algae and sponges. Two papers reported on antibiotic activity in compounds isolated from marine bacteria: Barsby et al. (2001) reported the isolation of the peptide bogorol A (8) from a culture of a marine Bacillus sp., which was active against methicillinresistant S. aureus (MIC=2 μg/mL) and vancomycin-resistant enterococcal strains (MIC =10 μg/mL). Because bogorol A represents a new cationic peptide antibiotic template the authors proposed that it might become "an attractive lead structure for SAR optimization". Asolkar et al. (2002) reported on the isolation of a novel macrolide antibiotic chalcomycin B (9) from the culture broth of a marine Streptomycete isolate which was particularly potent against S. aureus (MIC=0.39 μg/mL). Two papers reported on new antimicrobial peptides isolated from marine tunicates: Lee et al. (2001) discovered an unusual peptide, dicynthaurin (10), from hemocytes of the marine tunicate Halocynthia aurantium. Dicynthaurin (10), a peptide that contains an unpaired cysteine and forms covalent homodimers, was active against Gram-negative and Gram-positive bacteria. Jang et al. (2002) reported a new antimicrobial heterodimeric peptide halocidin (11) from the hemocytes of the solitary marine tunicate, H. aurantium, the same source of the peptide dicynthaurin. Although the investigators hypothesized that the main target of halocidin might be the bacterial cell membrane, this heterodimeric peptide demonstrated significant potency against methicillinresistant S. aureus and multidrug-resistant Pseudomonas aeruginosa. Three papers reported on the presence of antibacterial compounds in marine algae: a novel steroidal glycoside, iyengaroside-A (12), was isolated from the marine green alga Codium iyengarii and was shown to be slightly less potent than tetracycline against a battery of Gramnegative and Gram-positive bacteria. Vairappan et al. (2001) reported a new halogenated G15 acetogenin, lembyne-A (13), from the marine red alga Laurencia sp. that had antibacterial activity against a panel of 13 species of marine bacteria isolated from algal habitats. Suzuki et al. (2001) contributed two novel halogenated sesquiterpenoids, pannosanol (14) and pannosane (15), from the red alga Laurencia pannosa, which demonstrated antibacterial activity against 13 species of marine bacteria. Three antibiotic compounds were isolated from marine fungi: a novel chlorinated benzophenone antibiotic, pestalone (16), was isolated from a member of the marine fungus genus Pestalotia, in response to a bacterial challenge (Cueto et al., 2001) . Pestalone showed very potent antibiotic activity against methicillin-resistant S. aureus (MIC=37 ng/mL) and vancomycinresistant Enterococus faecium (MIC=78 ng/mL), suggesting that pestalone should be evaluated in advanced models of infection. Jadulco et al. (2001) reported the isolation of a new furan carboxylic acid, an acetyl derivative of sumiki's acid (17) from the marine fungus Cladosporium herbarum that was found to be active against Bacillus subtilis and S. aureus. Zopfiellamides A and B (19 and 20) , antimicrobial pyrrolidinone derivatives, were isolated from the marine fungus Zopfiella latipes (Daferner et al., 2002) . Although the zopfiellamides appeared to be moderately antibacterial to Gram-positive and Gram-negative bacteria (MIC = 2-10 μg/mL) they exhibited no cytotoxicity up to 100 μg/mL. Finally, the bromotyrosine antibiotic, zamastatin (18), was derived from the Okinawan sponge Pseudoceratina purpurea ) and while zamastatin affected the growth of the marine biofouling bacteria Rhodospirillum salexigens, it remains to be demonstrated that this compound will affect antibiotic-resistant bacteria.
Anticoagulant compounds
One paper was published during 2001-2002 on the anticoagulant properties of two marine polysaccharides, a decrease from our previous reviews (Mayer and Lehmann, 2000; Mayer and Hamann, 2002, 2004) . Pereira et al. (2002) reported a novel sulfated α-L-galactan (21) and a sulfated α-L-fucan (22) isolated from the crude egg jelly of the sea urchins Echinometra lucunter and Strongylocentrotus franciscanus collected in Brazil and the USA.
Interestingly, only the sulfated galactan had potent anticoagulant activity as shown by the enhancement of thrombin or factor Xa inhibition by antithrombin or heparin cofactor II, similar to heparin.
Antifungal compounds
Seven studies during 2001-2002 reported on the antifungal properties of 9 novel marine natural products, a slight increase from 1998-2000 (Mayer and Lehmann, 2000; Mayer and Hamann, 2002, 2004) . Antifungal activity was noted in novel compounds isolated from marine bacteria, sponges, sea cucumbers and fungi.
Two novel antifungal amides resulted from screening marine bacterial cultures against common fungal pathogens. Laboratory cultures of the marine bacterium Bacillus laterosporus produced the novel polyketides basiliskamides A and B (23 and 24) (Barsby et al., 2002) . Both compounds showed potent activity against Candida albicans (MIC=1.0 and 3.1 μg/mL, respectively) and Aspergillus fumigatus (MIC = 2.5 and 5.0 μg/mL, Two novel polyacetylenic acids, corticatic acids D and E (25 and 26) isolated from the marine sponge Petrosia corticata (Nishimura et al., 2002) were shown to inhibit geranylgeranyltransferase type I (GGTase I), an enzyme involved in fungal cell wall biosythesis. Interestingly, while corticatic acids D and E inhibited C. albicans with IC 50 values of 3.3 and 7.3 μM, the fact that there is little sequence identity between human and Candida GGTase I suggested that these marine compounds may become leads for novel and "selective antifungal agents". Swinhoeiamide A (27), a novel antifungal calyculin derivative was isolated from the marine sponge Theonella swinhoei (Edrada et al., 2002a) . Swinhoeiamide A showed strong antifungal activity towards C. albicans and A. fumigatus (MIC=1.2 and 1.0 μg/mL, respectively). Murray et al. (2001) reported the novel disulfated triterpene glycoside patagonicoside A (28) from the sea cucumber Psolus patagonicus that was active against the pathogenic fungus C. cucumerinum (apparent MIC=8 μg/spot), which may be the result of sulfate groups in the oligosaccharide chain.
Three novel marine antifungals resulted from screening marine fungal cultures against common fungal pathogens. An antifungal metabolite, 3,3′-oxybis [5-methyl-phenol] (29) was isolated from the fermentation broth of the filamentous marine fungus Keissleriella sp. (Liu et al., 2002a,b) . This novel metabolite moderately inhibited growth of the human pathogens C. albicans, Tricophyton rubrum and A. niger (MIC=10-80 μg/ml). A new antifungal polyester 15G256β (30) was isolated from the fermentation broth of the marine fungus Hypoxylon oceanicum (Schlingmann et al., 2002) . Although the exact molecular mechanism responsible for the reported antifungal activity has not been established, the polylactone was observed to potently inhibit a variety of phytopathogenic fungi (MIC=2 μg/mL). Culture filtrates of Penicillium cf. montanense obtained from the marine sponge Xestospongia exigua yielded a novel decalactone xestodecalactone B (31) (Edrada et al., 2002b) which was found to be active against the yeast C. albicans.
Antimalarial, antiplatelet, antiprotozoal and antituberculosis compounds
During 2001-2002 and as shown in Table 1 , 11 studies were reported in the area of antimalarial, antiprotozoal and antituberculosis pharmacology of structurally characterized marine natural products.
Eleven compounds depicted in Fig. 1 were shown to possess antimalarial activity. Moderate antimalarial activity (IC 50 =6.6 μg/mL) against the multidrug resistant Plasmodium falciparum (K1 strain) was reported for aigialomycins D (32), a new 14-membered resorcyclic macrolide isolated from the marine mangrove fungus Aigialus parvus BCC 5311 (Isaka et al., 2002) . As part of an ongoing program on biologically active substances from bioresources in Thailand, Chinworrungsee et al. (2001) reported the ophiobolane sesterterpene halorosellinic acid (33) from the marine fungus Halorosellinia oceanica BCC 5149. Halorosellinic acid demonstrated moderate antimalarial activity (IC 50 =13 μg/mL) against the parasite P. falciparum (K1, multidrug resistant strain). In vitro and in vivo antimalarial studies were conducted with the trypyrrole bacterial pigment heptyl prodigiosin (34), purified from the culture of a proteobacteria from a marine tunicate in the Philippines (Lazaro et al., 2002) . The investigators reported that the in vitro activity of heptyl prodigiosin against P. falciparum 3D7 was similar to chloroquine (IC 50 =0.07 vs. 0.015 μM, respectively). Interestingly, a single subcutaneous administration of 5-20 mg/kg heptyl prodigiosin significantly extended survival of P. berghei ANKA strain-infected mice, suggesting that "the molecule might be used as a lead compound". New enantiomers of ent-8-hydroxymanzamine A (35), manzamine F (36) and neo-kauluamine (37) were isolated from an undescribed Indo-Pacific sponge (El Sayed et al., 2001) . When assayed in vivo, ent-8-hydroxymanzamine A and neo-kauluamine reduced parasitemia in P. berghei-infected mice, with a concomitant increase in survival; additionally ent-8-hydroxymanzamine A and manzamine F inhibited Mycobacterium tuberculosis (MIC < 12.5 μg/mL). In vitro antimalarial activity (MIC=3.8-2.9 μg/mL) against P. falciparum (D6 and W2 clones) was reported for (S)-(+)-15-hydroxycurcuphenol (38), a microbial transformation product of the sesquiterpene (S)-(+)-curcuphenol isolated from the Jamaican sponge Didiscus oxeata and transformed using Kluyveromyces marxianus var. lactis (El Sayed et al., 2002) . Mizuno et al. (2002) extended the pharmacology of jasplakinolide (39), a cyclic peptide isolated from the marine sponge Jaspis sp. These investigators observed that jasplakinolide markedly decreased parasitemia of P. falciparum by virtue of "an apical protrusion that appears to interfere with the erythrocyte invasion by the merozoites" and whose mechanism of formation is possibly related to an increase in F-actin content of the merozoites treated with this marine agent. Wright et al. (2002) reported an extensive study on two novel alkaloids, lepadins E (40) and F (41) isolated from a tropical marine tunicate Didemnum sp., which showed significant antiplasmodial activity. Interestingly, the bioactivity of the two molecules against two P. falciparum strains (strain K1: IC 50 =0.4 and 0.2 μg/mL, respectively; strain NF5: IC 50 =0.9 and 0.3 μg/mL, respectively) appeared to be dependent on the configuration at C-2 and the nature of the functionality at C-3 in the decahydroquinoline, as well as the moderate inhibition of the p56 lck tyrosine kinase. A peroxide-containing metabolite, plakortide F (42) was isolated from the Jamaican sponge Plakortis sp. (Gochfeld and Hamann, 2001 ). The fact that plakortide F had significant in vitro activity against P. falciparum (D6 and W2 clones: IC 50 =0.48 and 0.39 μg/mL, respectively) suggested that the peroxide is necessary for antimalarial activity of this compound. Perry et al. (2001) contributed to antiprotozoal pharmacology by reporting the isolation of plakortolide G (43), a new peroxylactone from the Jamaican sponge Plakinastrella onkodes.
Plakortolide G at 10 μM exhibited 100% inhibition of infection by the obligate intracellular parasite Toxoplasma gondii, the cause of toxoplasmosis and concomitant serious pathology, including hepatitis, pneumonia, blindness, and severe neurological disorders that is especially true in individuals whose immune systems are compromised (e.g., AIDS patients).
Three novel compounds were contributed to the search for novel antituberculosis agents. A new bioactive diterpene, cyanthiwigin C (44), was isolated from the Jamaican sponge Myrmekioderma styx . At 6.25 μg/mL, cyanthiwigin C inhibited the growth of M. tuberculosis by 50%. Two new serrulatane diterpenes, erogorgiaene (45) and 7-hydroxyerogorgiaene (46), inhibited M. tuberculosis growth by 96% and 77% at a concentration of 12.5 and 6.25 μg/mL, respectively (Rodriguez and Ramirez, 2001 ). Bunc et al. (2002) contributed to the antiplatelet pharmacology of the water soluble polymeric 3-alkylpyridinium salts (47) isolated from the marine sponge Raniera sarai. These salts, previously shown to be cholinesterase inhibitors, appeared to aggregate in vivo inducing formation of "non-covalently bound supra-molecular structures", ultimately inducing blood coagulation, platelet aggregation and cytotoxicity in rats.
Antiviral compounds
As shown in Table 1 , interest in the antiviral pharmacology of marine natural products remained high during [2001] [2002] . During this two-year period, six novel marine compounds (Fig. 1) were reported to possess antiviral properties against human immunodeficiency (HIV), herpes simplex (HSV) and influenza viruses. Rudi et al. (2001) reported the isolation of clathsterol (48), a novel and active sulfated sterol from the Red Sea sponge Clathria sp., which was active against HIV-1 reverse transcriptase at 10 μM. An HIV-inhibitory cyclic depsipeptide, microspinosamide (49) was isolated from the marine sponge Sidonops microspinosa (Rashid et al., 2001 ). Microspinosamide inhibited the cytopathic effect of HIV-1 infection in a cell-based in vitro assay with an EC 50 of 0.2 μg/mL. Loya et al. (2002) reported an extensive study on the mechanism of action of poly-acetylenetriol (50), isolated from the marine sponge Petrosia sp. Polyacetylenetriol evidenced selective inhibition of the RNA-and DNA-dependent DNA polymerase activities of retroviral reverse transcriptases (IC 50 =0.95 μM), as compared to cellular DNA polymerases (IC 50 =2.6 μM). Furthermore, a reversible non-competitive mechanism involving a putative hydrophobic interaction was shown to play a critical role in the inhibition of the HIV-1 reverse transcriptase enzyme. Although polyacetylenetriol lacked sufficient specificity and thus could probably not be used as an anti-HIV agent, the authors concluded that "… structural modification of the side chains of the lead polyacetylenic molecule may produce new potent and selective anti-AIDS drugs". As a result of an ongoing program focused on the discovery of new "small molecule" inhibitors of HIV-1 integrase, Rowley et al. (2002) reported on the discovery of the sulfated-flavone glycosides, thalassiolins A-C (51, 52, and 53), isolated from the Caribbean sea grass Thalassia testudinum. Thalassiolin A, the most active compound of this series, inhibited HIV integrase catalyzed strand transfer (IC 50 =0.4 μM) as well as HIV replication in cell culture (IC 50 =30 μM). Interestingly, the presence of sulfated β-D-glucose functionality increased potency against the HIV integrase, while molecular modeling studies indicated that the probable binding site of the molecule was the catalytic core domain of the HIV-1 integrase.
As part of their search for novel influenza virus neuraminidase inhibitors, Nakao et al. (2001) reported three active sulfated calyceramides A-C (54, 55, and 56) isolated from the marine sponge Discodermia calyx. Interestingly, calyceramides A-C inhibited neuraminidase from bacterium Clostridium perfringens with IC 50 values of 0.4, 0.2 and 0.8 μg/mL, respectively, which was slightly more potent than 4-acetyl neuraminic acid (IC 50 =1.5 mg/mL). It remains to be determined if these compounds will also inhibit influenza virus neuraminidase with similar potency. Fig. 2. 
Marine compounds with anti-inflammatory and antidiabetic effects and affecting the cardiovascular, immune and nervous systems

Anti-inflammatory compounds
The anti-inflammatory pharmacology of the marine compounds halipeptins A and B, hymenamide C, petrosas-pongiolide and scytonemin was reported during 2001-2002, a slight decrease from our previous report (Mayer and Hamann, 2004) .
Two anti-inflammatory 17-membered cyclic depsipeptides, halipeptins A and B (57 and 58) were isolated from the marine sponge Haliclona sp. . Halipeptin A at 300 μg/kg potently and dose-dependently inhibited carrageenan-induced paw edema in a mouse model of inflammation. Although no mechanism of action study was reported, interestingly, indomethacin and naproxen showed an ED 50 of 12 and 40 mg/kg, respectively, in the same in vivo assay, thus suggesting that halipeptin A was "40 and 130 times more potent" than these clinically used non-steroidal anti-inflammatory agents. The immunomodulating activity of the marine cyclopeptide hymenamide C (59), isolated from the marine sponge Axinella carteri, was explored investigating its effects on neutrophils and macrophages . Although hymenamide C inhibition of human neutrophil degranulation (IC 50 =18 μM) was not particularly impressive, the authors noted that cyclosporine, a clinically used immunosuppressive cyclopeptide, exerted "weaker inhibitory effect on elastase release". A structure-activity relationship study completed with this cyclopeptide concluded a "non-receptorial mode of action" for hymenamide C and its synthetic analogs (Napolitano et al., 2002) . Dal Piaz et al. (2002) reported an extensive investigation of the mechanism of phospholipase A 2 (PLA 2 ) inactivation by the novel marine sesterterpene petrosaspongiolide M (60), a bioactive sesterterpene isolated from the marine sponge Petrosaspongia nigra. The reported results suggest that the PLA 2 α-amino terminal group of the IIe-1 residue is the only covalent binding site for petrosaspongiolide M, a compound that inhibits bee venom PLA 2 with an IC 50 =0.6 μM. Stevenson et al. (2002a,b) extended the pharmacology of scytonemin (61), a yellow-pigment isolated from marine cyanobacteria which demonstrated interesting anti-inflammatory and antiproliferative activities. In vitro, scytonemin inhibited both polo-like kinase 1 (IC 50 =2.3 μM) and protein kinase C β1 (IC 50 =5.4 μM), while in vivo, topical application of this novel pharmacophore reduced phorbol-ester induced mouse ear edema (IC 50 =10.9 μg/ear).
Antidiabetic and cardiovascular compounds
Only 3 reports during 2001-2002 contributed to the antidiabetic and cardiovascular pharmacology of marine natural products. Anderson et al. (2002) reported the purification, characterization and biological activity of insulins (62) from the European spotted dogfish, Scyliorhinus canalicula, and the hammerhead shark, Sphyrna lewini. Although the elasmobranch insulins were noted to be markedly different from human insulin, with 17 amino acid substitutions identified, all residues that are required for binding to the recombinant human insulin receptor were shown to be conserved. The bolus arterial injection of dogfish insulin caused a significant drop in blood glucose only after 12 h but it persisted for 48 h, indicating metabolic actions similar to those "described for mammalian insulin".
Contributions to the cardiovascular pharmacology of the marine natural products 2,5,6-tribromo-1-methylgramine (TBG) and lepadiformine were reported during . Iwata et al. (2001 extended the pharmacology of 2,5,6-tribromo-1-methylgramine (TBG) (63), a compound isolated from the marine bryozoan Zoobotryon pellucidum, by examining its effect on the contraction of the rat aorta. Interestingly, while at concentrations up to 10 μM the halogen-containing gramine analogue inhibited muscle contraction by affecting Ca 2+ entry, at 30 μM the inhibitory mechanism involved an increase in intracellular cyclic AMP. Juge et al. (2001) investigated the cardiovascular effects of lepadiformine (64), an alkaloid isolated from the marine ascidians Clavelina lepadiformis and C. moluccensis. Using in vivo arterial blood pressure recordings and electrocardiograms in anaesthetised rats and in situ peripheral vascular pressure recordings in perfused rabbit ear, they observed that lepadiformine had marked effects on the cardiocirculatory system, inducing bradycardia, prolonging electrocardiogram parameters, producing a transient fall of blood pressure in the rat and decreasing blood flow in the rabbit ear. The authors concluded that the pharmacological effects of lepadiformine might result from a reduction of the inward rectifying K + current, suggesting that this marine compound has "antiar-rhythmic properties" that warrant further investigation. Mayer et al. (2001) extended the pharmacology of the marine excitatory amino acid domoic acid (65), a glutamate and kainic acid analog which can cause amnesic shellfish poisoning in humans and is produced by the widely distributed marine diatom genus Pseudo-nitzschia. Domoic acid at in vitro concentrations that were toxic to neuronal cells (1 mM) was shown to trigger a limited activation of rat brain microglia, an immune cell type that contributes to circa 10% of the total glial population in the central nervous system, and the concomitant release of two potentially neurotoxic mediators, namely TNF-α and matrix metalloproteinase-9.
Compounds affecting the immune system
Compounds affecting the nervous system
Reports on both central and autonomic nervous system pharmacology of marine natural products during 2001-2002 studies involved antillatoxin B, dysiherbaine, N-3′-ethylaplysinopsin, neodysiherbaine A, gangliosides of Holothuria leucospilota, the peptides conantokins-G and L and manoalide.
Bioassay-guided fractionation of organic extracts from the marine cyanobacterium Lyngbya majuscula led to the isolation of the neurotoxic lipopeptide antillatoxin B (66), an analogue of the potent neurotoxin antillatoxin (Nogle et al., 2001) . Although antillatoxin B was a potent activator of voltage-sensitive sodium channel in a mouse neuro-2a neuroblastoma cell line (EC 50 =1.77 μM), its biological activity was 10-fold less than that of antillatoxin, probably as a result of a substitution of a larger N-methyl homo-phenylalanine residue for an N-methyl valine residue in the peptide-derived metabolite. An extensive characterization of the pharmacological properties of the potent epileptogenic amino acid dysiherbaine (67), isolated from the marine sponge Dysidea herbacea was reported by Sakai et al. (2001b) . Dysiherbaine, which demonstrated "potent convulsant activity", caused seizures upon injection into mice (ED 50 =13 pmol/mouse i.c.v) and was shown to be a non-NMDA-type glutamate receptor agonist with high selectivity for kainic acid receptors (IC 50 =210 nM) as well as mGluR5 receptors. The authors concluded that this novel marine amino acid might be useful for the evaluation of "physiological and pathological roles of non-NMDA receptors, especially kainic acid receptors, in the central nervous system". A new indole alkaloid, N-3′-ethylaplysinopsin (68), isolated from the Jamaican sponge Smenospongia aurea, was shown to potently bind to the human serotonin 5-HT 2C receptor subtype expressed in a mammalian cell line (Hu et al., 2002) . The authors suggest that the R2 functional groups at position 2′ may play an important role in regulating subtype selective binding to the 5-HT 2C receptor, a receptor found in high density in the choroid plexus, the site of cerebrospinal fluid production. Yamada et al. (2001) reported new gangliosides (HLG-1, HLG-2, and HLG-3) (69-71) from the sea cucumber Holothuria leucospilota which induced neurite growth outgrowth.
Although the molecular mechanism remains unexplored the ganglioside species displayed neuritogenic activity at 10 μM in the presence of nerve growth factor. Dorandeu et al. (2002) presented novel information on potential anticonvulsant pharmacology of the nonsteroidal sesterterpene manoalide (72), a well-known phospholipase A 2 inhibitor isolated from the marine sponge Luffariella variabilis. Manoalide was reported to fully and irreversibly inhibit the catalytic activity of crotoxin, the heterodimeric β-neurotoxin from the venom of the South American rattlesnake Crotalus durissus terrificus, preventing central neurotoxicity after intracerebroventricular injection and peripheral toxicity after intravenous injection. Sakai et al. (2001a) reported the isolation of a neodysiherbaine A (73), a new excitatory amino acid from the sponge D. herbacea. Neodysiherbaine A was observed to be a potent epileptogenic amino acid (ED 50 =15 pmol/mouse i.c.v), comparable to dysiherbaine, and a potent and novel non-NMDA-type glutamate receptor agonist with high selectivity for kainic acid receptors (IC 50 =66 nM). Two studies extended the pharmacology of the marine conantokins, the only natural biochemically characterized peptides known to be N-methyl-D-asparate (NMDA) antagonists and potent anticonvulsants. Wittekindt et al. (2001) investigated the binding of conantokin-G (74), a peptide derived from the venom of the marine cone snail Conus geographus, on recombinant NMDA receptors carrying point mutations within the glycine and glutamate binding pockets of the NR1 and NR2B subunits. Because mutations located in the glutamate binding site of the NR2B subunit were found to significantly affect conantokin-G binding, the investigators concluded that this peptide inhibited the NMDA receptor currents at the "glutamate binding site via a competitive mechanism". A new member of the conantokin peptide family, conantokin-L (75), was isolated and characterized from a heretofore unexamined species, the marine fish-hunting cone snail Conus lynceus . Conantokin-L had extensive sequence identities with conantokin-R and was a potent NMDA receptor antagonist in mammalian CNS neurons in culture. However, conantokin-L was a far less potent anticonvulsant in the audiogenic mouse model of epilepsy, probably as a result of the lack of C-terminal acids.
The authors note that the discovery of conantokin-L will definitely contribute to the development of a "clinically effective and well-tolerated NMDA antagonist that possesses both anticonvulsant and neuroprotective properties".
Marine compounds with miscellaneous mechanisms of action
The structures of marine compounds with miscellaneous mechanisms of action are presented in Fig. 3 . Interestingly and in contrast with the 75 chemicals included in Figs. 1 and 2 , this third group of 31 marine compounds includes not only nitrogen-containing compounds (i.e. proteins, peptides), terpenes and polyketides but also a few polysaccharides.
As shown in Table 3 , for some of these marine natural products, namely antillatoxin (77), azaspiracid-1 (79), bistratene A (80), bryostatin-1 (82), coscinosulfate (83), debromohymenialdisine (84), halenaquinol (88), halenaquinone (89), hectochlorin (90), maitotoxin (96), pectenotoxin-6 (98), sculezonone A and B (99 and 100), scytonemin (61), stolonoxides (101), xetospongin-C (105) and yessotoxin (106), both the pharmacological activity and molecular mechanism of action were reported.
In contrast, for the marine compounds aeroplysinin-1 (76), aplysiallene (78), bryoanthrathiophene (81), chlorogentisylquinone (85), discodermin A (86), farnesylhydroquinone (87), iantherans A and B (91 and 92), jaspaquinol (93), jasplankinolide (39), linckosides A and B (94 and 95), micropeptins (97), swinholide A (102) and wondonins A and B (103 and 104), while a pharmacological activity was investigated, no additional information was reported on the molecular mechanism of action.
Reviews on marine pharmacology
Several reviews covering selected aspects of marine pharmacology and toxicology were published during [2001] [2002] : the chemistry and biological function of natural marine toxins (Yasumoto, 2001 ); a retrospective on the conotoxins (Olivera and Cruz, 2001 ); α-conotoxins as pharmacological tools and potential drug leads (Dutton and Craik, 2001) ; ciguatera fish poisoning (Hokama and Yoshikawa-Ebesu, 2001 ); toxic marine microalgae (Daranas et al., 2001) ; advances in chemical and biological research with marine indoles and carbazole alkaloids (Pindur and Lemster, 2001) ; biologically active marine proteins (O'Keefe, 2001) ; bioactive marine compounds from coral reef invertebrates (Higa et al., 2001) ; glycolipids with immunomodulating activity from marine sponges (Costantino et al., 2001) ; marine lipids and coronary heart disease (Colquhoun, 2001) ; anticoagulant properties of sulfated glycosaminoglycans (Pavao, 2002) ; sea-anemone pore-forming proteins and their pharmacological and medical use (Anderluh and Menestrina, 2001) ; cytolytic peptide and protein toxins from sea anemones (Anderluh and Macek, 2002) ; okadaic acid as the archetypal serine/threonine protein phosphatase inhibitor (Dounay and Forsyth, 2002) and useful tool for studying cellular processes ; marine microorganisms for the production of bioactive metabolites (Wagner-Dobler et al., 2002) ; cyanobacterial toxins and their implications for human health (Rao et al., 2002) ; the pharmacological activity of fish venoms (Church and Hodgson, 2002) ; and the chemistry of marine natural products (Faulkner, 2001; Faulkner, 2002) .
Conclusion
Although during 2001-2002 no new marine natural product was approved for patient care by the U.S. Food and Drug Administration, the present review documents the fact that during 2001-2002 preclinical pharmacological research with marine chemicals continued to proceed at a very active pace, involving both natural product chemists and pharmacologists from 29 countries including the United States. Although this review has mainly focused on recent developments in the preclinical pharmacology of 106 marine natural products, the reader should be aware that concomitant to the mechanistic characterization of marine natural products, the issues of supply, formulation, and manufacturing represent important challenges that need to be met for the successful development of novel pharmaceutical agents. These issues were approached in 2002 by three companies involved in the development of novel pharmaceuticals from marine sources GarciaFernandez et al., 2002; Mayer, 2002; Sennett et al., 2002) . The structure for jasplankinolide (39) is shown in Fig. 1 . The structure for scytonemin (61) is shown in Fig. 2 .
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